This article provides details on the free float of Iron Horse Acquisitions II Corp. (BOATS:IRHOR). It appears to be a stub or a financial data point from TradingView, indicating that the market is closed and no trades have occurred for this entity.

Wall Street Zen has downgraded Transdigm Group (NYSE:TDG) from a "buy" to a "hold" rating, contributing to a mixed analyst sentiment despite a consensus "Moderate Buy" rating and a target price of $1,524.18. This comes even as Transdigm reported strong quarterly results with EPS of $9.85 and revenue of $2.54 billion, an 18.3% year-over-year increase. Insider selling has also been significant, with executives selling shares worth approximately $51.4 million over the past three months.

Wall Street Zen has upgraded Leidos (NYSE:LDOS) stock from "hold" to "buy," contributing to a generally positive analyst outlook. The company recently exceeded quarterly earnings expectations with an EPS of $3.13 and revenue of $4.40 billion, also raising its FY 2026 EPS guidance to $12.10-$12.50. Despite recent stock pressure, trading near a 52-week low, the consensus rating is a "Moderate Buy" with a target price of $187.50.

Wall Street Zen has upgraded Wells Fargo & Company (NYSE:WFC) from "sell" to "hold," indicating a less negative outlook. While the consensus rating for WFC is "Moderate Buy" with an average price target of $97.53, several other analysts have recently trimmed their price targets. The bank recently surpassed quarterly EPS estimates but fell short on revenue, and faces regulatory scrutiny from a DOJ subpoena related to "debanking" allegations.

Wall Street Zen has upgraded Amgen (NASDAQ:AMGN) from "hold" to "buy," contributing to a mixed but generally positive analyst sentiment for the company. Despite the upgrade, Amgen's average rating remains "Hold" with a consensus target price of $354.12, according to MarketBeat data. The company recently surpassed Q1 expectations with strong EPS and revenue, and its pipeline shows promise in areas like eye disease and obesity, though regulatory risks like a proposed FDA withdrawal for Tavneos remain a concern.

H55 has delivered three certification-grade hybrid-electric battery modules to Pratt & Whitney Canada for the RTX Hybrid-Electric Flight Demonstrator program. This delivery marks a significant step towards certified electric flight, moving beyond conceptual development to industrial-scale production. H55 emphasizes that meeting strict certification, safety, and production standards is now critical for the commercial deployment of electric aviation technology, with the company having logged over 2,000 flight hours without battery-related incidents.

RBC Capital analyst Trung Huynh upgraded Pfizer (NYSE: PFE) from ‘Underperform’ to ‘Sector Perform’ with a $25 price target, despite an unchanged overall investment outlook. The upgrade is attributed to the stock's recent 8% drop, making its 9-times forward earnings valuation more attractive, and its robust 6.57% dividend yield which is seen as a downside mitigator. Upcoming catalysts include Sigvotatug vedotin in lung cancer and mevro later this year, alongside strong Q1 fundamentals that could lead to a 2026 guidance upgrade.

Mizuho has increased its price target for CVS Health (CVS) from $110 to $115, maintaining an 'Outperform' rating. This adjustment reflects a belief that the managed care industry is entering a more stable policy environment, allowing investors to focus on company fundamentals. CVS Health, a Fortune 500 company, also offers an attractive annual dividend yield of 2.65%.

Morgan Stanley CEO Ted Pick announced a new goal of $10 trillion in wealth management assets, building on the firm's strong first-quarter 2026 performance. This revised target focuses solely on the wealth division, surpassing former CEO James Gorman's combined goal. The wealth management division currently boasts $9 trillion in client assets, with significant contributions from advisor-led channels, workplace accounts, and E*TRADE accounts.

Wells Fargo has lowered its price target for PepsiCo (PEP) from $160 to $150, while maintaining an 'Equal Weight' rating. This adjustment reflects concerns about ongoing macroeconomic uncertainty and its potential impact on consumer spending, despite PepsiCo's strong Q1 2026 performance and reaffirmed FY 2026 guidance. The firm believes PepsiCo's goal of accelerating sales growth through 2026 may be challenging.